busulfan has been researched along with HbS Disease in 25 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "Thirty-four patients had thalassemia major and 4 had SCA." | 5.43 | Allogeneic Stem Cell Transplantation in Congenital Hemoglobinopathies Using a Tailored Busulfan-Based Conditioning Regimen: Single-Center Experience. ( Ben-Arush, M; Elhasid, R; Khalil, A; Rowe, JM; Zaidman, I, 2016) |
| "Busulfan (Bu) is an integral part of conditioning regimens for patients with sickle cell anemia (SCA) undergoing transplantation." | 2.80 | New insights into the pharmacokinetics of intravenous busulfan in children with sickle cell anemia undergoing bone marrow transplantation. ( Alfieri, C; Andreani, M; De Angelis, G; Dinallo, V; Gallucci, C; Gaziev, J; Ialongo, C; Isgrò, A; Lucarelli, G; Marziali, M; Mozzi, AF; Nguyen, L; Paciaroni, K; Petain, A; Ribersani, M; Sodani, P; Testi, M, 2015) |
| "Seven of 21 patients with sickle cell anemia developed neurologic complications 5 to 243 days (median, 33 days) after allogeneic marrow transplantation." | 2.68 | Neurologic complications after allogeneic marrow transplantation for sickle cell anemia. ( Bernaudin, F; Bunin, N; Johnson, FL; Lenarsky, C; Ohene-Frempong, K; Powars, D; Souillet, G; Sullivan, KM; Vannier, JP; Walters, MC, 1995) |
| "Thiotepa has improved engraftment when added to this regimen, however the minimum effective dose (MED) of thiotepa to achieve engraftment while minimizing toxicities has not been well established." | 1.91 | Feasibility study of busulfan, fludarabine, and thiotepa conditioning regimen for allogeneic hematopoietic stemcell transplantationfor children and young adults with nonmalignant disorders. ( Cascio, E; Castillo, P; Farhadfar, N; Fort, J; Fraser, A; Horn, B; Lamba, J; Moore-Higgs, G; Slayton, W, 2023) |
| "Busulfan was considered the cause in the first reported case because the transgene was not present in the AML/MDS." | 1.62 | Leukemia after gene therapy for sickle cell disease: insertional mutagenesis, busulfan, both, or neither. ( DeBaun, MR; Jones, RJ, 2021) |
| " Conditioning with treosulfan alone at nonmyeloablative dosing (3." | 1.48 | Bone Marrow Transplantation after Nonmyeloablative Treosulfan Conditioning Is Curative in a Murine Model of Sickle Cell Disease. ( Devadasan, D; Goldman, FD; Pawlik, KM; Sun, CW; Townes, TM; Westin, ER; Wu, LC, 2018) |
| "Thirty-four patients had thalassemia major and 4 had SCA." | 1.43 | Allogeneic Stem Cell Transplantation in Congenital Hemoglobinopathies Using a Tailored Busulfan-Based Conditioning Regimen: Single-Center Experience. ( Ben-Arush, M; Elhasid, R; Khalil, A; Rowe, JM; Zaidman, I, 2016) |
| "Busulfan (BU) has a narrow therapeutic window and the average concentration of BU at steady state (Css) is critical for successful engraftment in children receiving BU as part of the preparative regimen for allogeneic transplants." | 1.40 | Targeted Busulfan therapy with a steady-state concentration of 600-700 ng/mL in patients with sickle cell disease receiving HLA-identical sibling bone marrow transplant. ( Brown, V; Bruce, K; Calder, C; Domm, J; Evans, M; Frangoul, H; Ho, R; Kassim, A; Maheshwari, S; Manes, B; Yang, E; Yeh, RF, 2014) |
| " Our experience shows that targeting busulfan AUC above the range used in previous multicenter trials appears safe and may contribute to sustained engraftment in SCD." | 1.37 | Safety and efficacy of targeted busulfan therapy in children undergoing myeloablative matched sibling donor BMT for sickle cell disease. ( Chiang, KY; Haight, AE; Horan, J; Hutcherson, D; McPherson, ME; Olson, E, 2011) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 5 (20.00) | 18.2507 |
| 2000's | 2 (8.00) | 29.6817 |
| 2010's | 15 (60.00) | 24.3611 |
| 2020's | 3 (12.00) | 2.80 |
| Authors | Studies |
|---|---|
| Fraser, A | 1 |
| Castillo, P | 1 |
| Cascio, E | 1 |
| Moore-Higgs, G | 1 |
| Farhadfar, N | 1 |
| Fort, J | 1 |
| Slayton, W | 1 |
| Lamba, J | 1 |
| Horn, B | 1 |
| Remy, A | 1 |
| Théorêt, Y | 1 |
| Ansari, M | 1 |
| Bittencourt, H | 1 |
| Ducruet, T | 1 |
| Nava, T | 1 |
| Pastore, Y | 1 |
| Rezgui, MA | 1 |
| Krajinovic, M | 1 |
| Kleiber, N | 1 |
| Jones, RJ | 1 |
| DeBaun, MR | 1 |
| Pawlowska, AB | 1 |
| Cheng, JC | 1 |
| Karras, NA | 1 |
| Sun, W | 1 |
| Wang, LD | 1 |
| Bell, AD | 1 |
| Gutierrez, L | 1 |
| Rosenthal, J | 1 |
| Rangarajan, HG | 1 |
| Abu-Arja, R | 1 |
| Pai, V | 1 |
| Guilcher, GMT | 1 |
| Soni, S | 2 |
| Devadasan, D | 1 |
| Sun, CW | 1 |
| Westin, ER | 1 |
| Wu, LC | 1 |
| Pawlik, KM | 1 |
| Townes, TM | 1 |
| Goldman, FD | 1 |
| Demirci, S | 1 |
| Mora, JJH | 1 |
| Yapundich, M | 1 |
| Drysdale, C | 1 |
| Gamer, J | 1 |
| Nassehi, T | 1 |
| Bonifacino, AC | 1 |
| Krouse, AE | 1 |
| Linde, NS | 1 |
| Donahue, RE | 1 |
| Tisdale, JF | 1 |
| Uchida, N | 1 |
| Radhakrishnan, K | 2 |
| Bhatia, M | 2 |
| Geyer, MB | 2 |
| Del Toro, G | 2 |
| Jin, Z | 2 |
| Baker, C | 2 |
| Harrison, L | 1 |
| Morris, E | 2 |
| Baxter-Lowe, LA | 2 |
| Cairo, MS | 2 |
| Maheshwari, S | 1 |
| Kassim, A | 1 |
| Yeh, RF | 1 |
| Domm, J | 1 |
| Calder, C | 1 |
| Evans, M | 1 |
| Manes, B | 1 |
| Bruce, K | 1 |
| Brown, V | 1 |
| Ho, R | 1 |
| Frangoul, H | 1 |
| Yang, E | 1 |
| Gross, TG | 1 |
| Rangarajan, H | 1 |
| Baker, KS | 1 |
| Sturm, M | 1 |
| Rhodes, M | 1 |
| Satwani, P | 1 |
| George, D | 1 |
| Garvin, J | 1 |
| Zuckerman, W | 1 |
| Lee, MT | 1 |
| Licursi, M | 1 |
| Hawks, R | 1 |
| Smilow, E | 1 |
| Schwartz, J | 1 |
| Gaziev, J | 1 |
| Isgrò, A | 1 |
| Mozzi, AF | 1 |
| Petain, A | 1 |
| Nguyen, L | 1 |
| Ialongo, C | 1 |
| Dinallo, V | 1 |
| Sodani, P | 1 |
| Marziali, M | 1 |
| Andreani, M | 1 |
| Testi, M | 1 |
| Paciaroni, K | 1 |
| Gallucci, C | 1 |
| De Angelis, G | 1 |
| Alfieri, C | 1 |
| Ribersani, M | 1 |
| Lucarelli, G | 1 |
| Horan, JT | 1 |
| Haight, A | 1 |
| Dioguardi, JL | 1 |
| Brown, C | 1 |
| Grizzle, A | 1 |
| Shelman, C | 1 |
| Kanter, J | 1 |
| Hale, G | 1 |
| Nieder, M | 1 |
| Benton, M | 1 |
| Kasow, KA | 1 |
| Abraham, A | 1 |
| Chiang, KY | 2 |
| Strocchio, L | 1 |
| Zecca, M | 1 |
| Comoli, P | 1 |
| Mina, T | 1 |
| Giorgiani, G | 1 |
| Giraldi, E | 1 |
| Vinti, L | 1 |
| Merli, P | 1 |
| Regazzi, M | 1 |
| Locatelli, F | 1 |
| Elchuri, SV | 1 |
| Williamson, RS | 1 |
| Clark Brown, R | 1 |
| Haight, AE | 2 |
| Spencer, JB | 1 |
| Buchanan, I | 1 |
| Hassen-Schilling, L | 1 |
| Brown, MR | 1 |
| Mertens, AC | 1 |
| Meacham, LR | 1 |
| Zaidman, I | 1 |
| Rowe, JM | 1 |
| Khalil, A | 1 |
| Ben-Arush, M | 1 |
| Elhasid, R | 1 |
| McPherson, ME | 1 |
| Hutcherson, D | 1 |
| Olson, E | 1 |
| Horan, J | 1 |
| Donnez, J | 1 |
| Squifflet, J | 1 |
| Pirard, C | 1 |
| Jadoul, P | 1 |
| Dolmans, MM | 1 |
| Kean, LS | 2 |
| Manci, EA | 1 |
| Perry, J | 1 |
| Balkan, C | 1 |
| Coley, S | 1 |
| Holtzclaw, D | 1 |
| Adams, AB | 2 |
| Larsen, CP | 2 |
| Hsu, LL | 2 |
| Archer, DR | 2 |
| Walters, MC | 1 |
| Sullivan, KM | 1 |
| Bernaudin, F | 3 |
| Souillet, G | 2 |
| Vannier, JP | 2 |
| Johnson, FL | 1 |
| Lenarsky, C | 1 |
| Powars, D | 1 |
| Bunin, N | 1 |
| Ohene-Frempong, K | 1 |
| Vergauwen, P | 1 |
| Ferster, A | 1 |
| Valsamis, J | 1 |
| Chanoine, JP | 1 |
| Plouvier, E | 1 |
| Lemerle, S | 1 |
| Michel, G | 1 |
| Bordigoni, P | 1 |
| Lutz, P | 1 |
| Kuentz, M | 2 |
| Hernigou, P | 1 |
| Reinert, P | 1 |
| Vernant, JP | 1 |
| Durham, MM | 1 |
| Perry, JR | 1 |
| Dillehay, D | 1 |
| Pearson, TC | 1 |
| Waller, EK | 1 |
| Vermylen, C | 1 |
| Cornu, G | 1 |
| Philippe, M | 1 |
| Ninane, J | 1 |
| Borja, A | 1 |
| Latinne, D | 1 |
| Ferrant, A | 1 |
| Michaux, JL | 1 |
| Sokal, G | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase 1/2 Study Evaluating Gene Therapy by Transplantation of Autologous CD34+ Stem Cells Transduced Ex Vivo With the LentiGlobin BB305 Lentiviral Vector in Subjects With Severe Sickle Cell Disease[NCT02140554] | Phase 1/Phase 2 | 50 participants (Anticipated) | Interventional | 2014-08-31 | Active, not recruiting | ||
| Allogeneic Stem Cell Transplant to Induce Mixed Donor Chimerism in Patients With Sickle Cell Disease and Thalassemia[NCT00408447] | Phase 2 | 53 participants (Actual) | Interventional | 2004-09-30 | Active, not recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
4 trials available for busulfan and HbS Disease
| Article | Year |
|---|---|
Reduced toxicity, myeloablative conditioning with BU, fludarabine, alemtuzumab and SCT from sibling donors in children with sickle cell disease.
Topics: Adolescent; Adult; Alemtuzumab; Anemia, Sickle Cell; Antibodies, Monoclonal, Humanized; Antineoplast | 2014 |
New insights into the pharmacokinetics of intravenous busulfan in children with sickle cell anemia undergoing bone marrow transplantation.
Topics: Adolescent; Allografts; Anemia, Sickle Cell; Bone Marrow Transplantation; Busulfan; Child; Child, Pr | 2015 |
Using fludarabine to reduce exposure to alkylating agents in children with sickle cell disease receiving busulfan, cyclophosphamide, and antithymocyte globulin transplant conditioning: results of a dose de-escalation trial.
Topics: Adolescent; Allografts; Anemia, Sickle Cell; Antilymphocyte Serum; Busulfan; Child; Child, Preschool | 2015 |
Neurologic complications after allogeneic marrow transplantation for sickle cell anemia.
Topics: Adolescent; Adult; Anemia, Sickle Cell; Anticonvulsants; Antilymphocyte Serum; Bone Marrow Transplan | 1995 |
21 other studies available for busulfan and HbS Disease
| Article | Year |
|---|---|
Feasibility study of busulfan, fludarabine, and thiotepa conditioning regimen for allogeneic hematopoietic stemcell transplantationfor children and young adults with nonmalignant disorders.
Topics: Anemia, Sickle Cell; Busulfan; Child; Feasibility Studies; Hematopoietic Stem Cell Transplantation; | 2023 |
Is Busulfan Clearance Different in Patients With Sickle Cell Disease? Let's Clear Up That Case With Some Controls.
Topics: Adolescent; Adult; Anemia, Sickle Cell; Busulfan; Case-Control Studies; Child; Child, Preschool; Cro | 2021 |
Leukemia after gene therapy for sickle cell disease: insertional mutagenesis, busulfan, both, or neither.
Topics: Alkylating Agents; Anemia, Sickle Cell; Busulfan; Clinical Trials as Topic; Gene Editing; Genetic Th | 2021 |
HLA Haploidentical Stem Cell Transplant with Pretransplant Immunosuppression for Patients with Sickle Cell Disease.
Topics: Adolescent; Anemia, Sickle Cell; Antilymphocyte Serum; Busulfan; Cohort Studies; Dexamethasone; Graf | 2018 |
Outcomes of Unrelated Donor Stem Cell Transplantion with Post-Transplant Cyclophosphamide for Graft-versus-Host Disease Prophylaxis in Patients with Severe Sickle Cell Disease.
Topics: Adolescent; Anemia, Sickle Cell; Antilymphocyte Serum; Antineoplastic Combined Chemotherapy Protocol | 2018 |
Bone Marrow Transplantation after Nonmyeloablative Treosulfan Conditioning Is Curative in a Murine Model of Sickle Cell Disease.
Topics: Anemia, Sickle Cell; Animals; Antibodies; Antineoplastic Agents, Alkylating; Bone Marrow Transplanta | 2018 |
Fetal hemoglobin and F-cell variance in mobilized CD34
Topics: Allografts; Anemia, Sickle Cell; Animals; Antigens, CD34; Busulfan; Erythrocytes, Abnormal; Fetal He | 2019 |
Busulfan, fludarabine, and alemtuzumab conditioning and unrelated cord blood transplantation in children with sickle cell disease.
Topics: Alemtuzumab; Anemia, Sickle Cell; Antibodies, Monoclonal, Humanized; Busulfan; Child; Child, Prescho | 2013 |
Targeted Busulfan therapy with a steady-state concentration of 600-700 ng/mL in patients with sickle cell disease receiving HLA-identical sibling bone marrow transplant.
Topics: Adolescent; Age Factors; Anemia, Sickle Cell; Antilymphocyte Serum; Bone Marrow Transplantation; Bus | 2014 |
Outcomes of matched sibling donor hematopoietic stem cell transplantation for severe sickle cell disease with myeloablative conditioning and intermediate-dose of rabbit anti-thymocyte globulin.
Topics: Adolescent; Anemia, Sickle Cell; Animals; Antilymphocyte Serum; Busulfan; Child; Child, Preschool; F | 2014 |
Treosulfan-based conditioning regimen for allogeneic haematopoietic stem cell transplantation in children with sickle cell disease.
Topics: Adolescent; Anemia, Sickle Cell; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Child; Ch | 2015 |
The effects of hydroxyurea and bone marrow transplant on Anti-Müllerian hormone (AMH) levels in females with sickle cell anemia.
Topics: Adolescent; Anemia, Sickle Cell; Anti-Mullerian Hormone; Antisickling Agents; Biomarkers; Bone Marro | 2015 |
Allogeneic Stem Cell Transplantation in Congenital Hemoglobinopathies Using a Tailored Busulfan-Based Conditioning Regimen: Single-Center Experience.
Topics: Adolescent; Adult; Anemia, Sickle Cell; beta-Thalassemia; Busulfan; Child; Child, Preschool; Chimeri | 2016 |
Safety and efficacy of targeted busulfan therapy in children undergoing myeloablative matched sibling donor BMT for sickle cell disease.
Topics: Adolescent; Anemia, Sickle Cell; Bone Marrow Transplantation; Busulfan; Child; Child, Preschool; Chi | 2011 |
Restoration of ovarian function after allografting of ovarian cortex between genetically non-identical sisters.
Topics: Adolescent; Adult; Anemia, Sickle Cell; Antineoplastic Agents, Alkylating; beta-Thalassemia; Busulfa | 2010 |
Chimerism and cure: hematologic and pathologic correction of murine sickle cell disease.
Topics: Anemia, Sickle Cell; Animals; Bone Marrow; Bone Marrow Transplantation; Busulfan; Cell Survival; Dis | 2003 |
Primary ovarian failure after prepubertal marrow transplant in a girl.
Topics: Adolescent; Anemia, Sickle Cell; Bone Marrow Transplantation; Busulfan; Cyclophosphamide; Female; Hu | 1994 |
Bone marrow transplantation (BMT) in 14 children with severe sickle cell disease (SCD): the French experience. GEGMO.
Topics: Adolescent; Africa; Anemia, Sickle Cell; Bone Marrow Purging; Bone Marrow Transplantation; Busulfan; | 1993 |
Bone-marrow transplantation in sickle-cell disease. Effect on osteonecrosis: a case report with a four-year follow-up.
Topics: Adolescent; Anemia, Hemolytic; Anemia, Sickle Cell; Bone Marrow Transplantation; Bone Regeneration; | 1997 |
A cure for murine sickle cell disease through stable mixed chimerism and tolerance induction after nonmyeloablative conditioning and major histocompatibility complex-mismatched bone marrow transplantation.
Topics: Abatacept; Anemia, Sickle Cell; Animals; Antibodies; Antigens, CD; Antigens, Differentiation; Bone M | 2002 |
Bone marrow transplantation in sickle cell anaemia.
Topics: Adolescent; Adult; Anemia, Sickle Cell; Bone Marrow Transplantation; Busulfan; Child; Child, Prescho | 1991 |